Dynavax Technologies and Berna Biotech Announce Collaboration
06-Nov-2003
Berna uses the proprietary Hansenula polymorpha yeast Expression System for the production of HBsAg antigen. This is the active ingredient of Berna's hepatitis B vaccine. More than 300 million doses of this vaccine have been supplied worldwide since 1996. No financial details were disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.